Table 2.
Cases with concomitant genomic alterations.
| Patient’s Classification (Standard Approach) | NGS Genomic Alteration | AF | Clinical Significance | PFS1 | OS |
|---|---|---|---|---|---|
| UC | KRAS c.35G > T | 26.7 | Pathogenic | 7.1 | 9 |
| TP53 c.839G > A | 13.0 | Likely pathogenic | |||
| UC | BRAF c.1799T > A | 50.4 | Pathogenic | 4 | 15 |
| TP53 c.476C > G | 39.2 | Uncertain | |||
| UC | KRAS c.182A > G | 8.8 | Pathogenic | 2 | 5 |
| TP53 c.461G > T | 24.7 | Uncertain | |||
| STK11p.Glu199Asp | 12.8 | Pathogenic | |||
| UC | ERBB2 c.2310_2311insGCATAC | 20 | Not found | 0 | 3 |
| TP53 c.1024C > T | 21 | Pathogenic | |||
| UC | KRAS c.38_39delGCinsAA | 14.2 | n/a | 0 | 4 |
| ERBB4 c.1033G > T | 14.9 | n/a | |||
| EGFR | EGFR c.2235_2249del15 | 34.6 | Pathogenic | 10.1 | 37 (NR) |
| PIK3CA c.1633G > A | 27.8 | Pathogenic | |||
| EGFR | EGFR c.2236_2250del15 | 11.1 | Pathogenic | 8 | 24 |
| KRAS c.182A > G | 0.38 | Pathogenic | |||
| EGFR | EGFR c.2240_2257del18 | 67.2 | Pathogenic | 9.4 | 40 (NR) |
| EGFR c.2369C > T | 0.6 | Pathogenic | |||
| EGFR | EGFR c.2239_2248del | 66 | Pathogenic | 16.6 | NR |
| ALK c.3512T > A | 0.08 | Pathogenic | |||
| EML4-ALK | TP53 c.538G > T | 37.8 | Pathogenic | 9.7 | 42 |
| EML4-ALK | TP53 c.524G > A | 2.13 | Pathogenic | 16 | 31 |
| EML4-ALK | KRAS c.35G > T | 27.4 | Pathogenic | NE | 3 |
| EML4-ALK | KRAS c.35G > T | 11.7 | Pathogenic | 7 | 47 |
| EML4-ALK | KRAS c.35G > A | 6.1 | Pathogenic | NE | 2 |
UC, unclassifiable; AF, allelic frequency; PFS1, Progression Free Survival related to 1st Line therapy; OS, Overall survival, NE, not evaluated; NR, not reached: n/a, not available.